Cadent Therapeutics Starts Phase I Trial with Essential Tremor Drug Candidate, Secures $40 Million to Advance Pipeline for Movement and Cognitive Disorders – CBI

Homepage / Press Release / Cadent Therapeutics Starts Phase I Trial with Essential Tremor Drug Candidate, Secures $40 Million to Advance Pipeline for Movement and Cognitive Disorders

Press Release

Cadent Therapeutics Starts Phase I Trial with Essential Tremor Drug Candidate, Secures $40 Million to Advance Pipeline for Movement and Cognitive Disorders